DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/v9kk6s/retinal) has announced the addition of the "Retinal Degeneration Global Clinical Trials Review, H2, 2015" report to their offering.
"Retinal Degeneration Global Clinical Trials Review, H2, 2015" provides an overview of the Retinal Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Retinal Degeneration.
The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The report provides enrollment trends for the past five years
-
The report provides latest news for the past three months
Companies Mentioned
- Santhera Pharmaceuticals Holding AG
- Pfizer Inc.
- Oraya Therapeutics, Inc.
- NightstaRx Ltd
- Inotek Pharmaceuticals Corporation
- China Shenghuo Pharmaceutical Holdings, Inc.
- Applied Genetic Technologies Corporation
- AmpliPhi Biosciences Corporation
- Allergan Plc
- Alberta Innovates- Health Solutions
For more information visit http://www.researchandmarkets.com/research/v9kk6s/retinal
